Thromboprophylaxis in outpatients with COVID-19: a safe bet or tilting at windmills?

Minerva Cardiol Angiol. 2022 Feb;70(1):1-4. doi: 10.23736/S2724-5683.21.05914-7. Epub 2021 Oct 29.

Authors

John G Rizk¹, Giuseppe Lippi², Youssef Rizk³

Affiliations

¹ Arizona State University, Edson College, Phoenix, AZ, USA - john.rizk@lau.edu.
² Section of Clinical Biochemistry, University of Verona, Verona, Italy.
³ Division of Family Medicine, Department of Internal Medicine, St. John's Hospital, Lebanese American University Medical Center, Beirut, Lebanon.

PMID: 34713682
DOI: 10.23736/S2724-5683.21.05914-7

No abstract available

MeSH terms

Anticoagulants / adverse effects
COVID-19* / prevention & control
Humans
Outpatients
SARS-CoV-2
Venous Thromboembolism* / prevention & control

Substances

Anticoagulants